SpaceX Stock Slides After IPO Rally as Valuation Concerns Grow 
Qantas Unveils Wellness-Focused Nonstop Sydney-London Flights to Reduce Jet Lag 
Frank Stronach Found Guilty of Sexual Assault and Indecent Assault in Ontario Court 
Kingboard Holdings Shares Surge After HK$11.77 Billion Block Trade to Expand PCB and AI Supply Chain Business 
JPMorgan Sees Strong Strategic Value in Potential AbbVie Acquisition of Apogee Therapeutics 
Carro Expands Into Australia With Acquisition of Used-Car Platform CarPlace 
Trump Says Anthropic No Longer Seen as National Security Threat 
Ukrainian Drone Makers Target Japan and Asia Defense Market 
US-Iran De-Escalation Shifts Washington’s Focus to AI Regulation and Crypto Legislation 
GM and Lockheed Martin Partner to Strengthen U.S. Defense Manufacturing Capacity 
Samsung Gains Interest from BYD, Google, AMD as AI Chip Demand Strains TSMC Capacity 
US Raises Concerns Over Possible ASML EUV Machine Transfer to China 
Hyundai to Acquire SoftBank’s Remaining Boston Dynamics Stake for $325 Million 
TD Bank Expands Employee Monitoring Software to Boost Productivity Amid Privacy Concerns 
SK Hynix Overtakes Samsung as South Korea’s Most Valuable Company 
BHP Shares Fall as Jansen Potash Project Costs Surge 
China Adds MP Materials, USA Rare Earth to Export Control List Amid Escalating U.S.-China Trade Tensions 
CVS Health (NYSE: CVS) announced Friday that it has reduced employee bonuses due to lower-than-expected profits in 2024. The healthcare giant faced mounting costs, particularly from its Medicare plans, impacting overall financial performance.
A company spokesperson stated, “We did not meet our financial goals in 2024, and that’s reflected in our corporate bonus.”
CVS experienced a surge in Medicare enrollments, leading to increased expenses. The company also struggled with higher medical service utilization, a shift in quality ratings, and elevated costs from sicker Medicaid members. These factors contributed to financial setbacks, prompting executive changes and restructuring efforts.
In October, CVS replaced CEO Karen Lynch with longtime company executive David Joyner following investor pressure, including from activist Glenview Capital. Joyner has since initiated cost-cutting measures and appointed a new insurance head to stabilize operations.
Despite financial challenges, CVS recently exceeded Wall Street’s fourth-quarter profit expectations and provided an annual forecast aligning with analyst estimates. This signals potential improvement under the new leadership.
As CVS navigates economic headwinds, its strategic adjustments will be crucial in restoring growth and shareholder confidence.
